Published in Structure on July 01, 2004
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem (2009) 3.88
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 3.60
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A (2004) 3.27
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc (2010) 2.50
Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature (2012) 2.21
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem (2008) 2.12
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem (2008) 2.09
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep (2007) 2.01
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
Isoform-selective histone deacetylase inhibitors. Chem Soc Rev (2008) 1.72
Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta (2008) 1.69
Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry (2008) 1.68
Ketone bodies as signaling metabolites. Trends Endocrinol Metab (2013) 1.37
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr Opin Struct Biol (2011) 1.35
A genome-wide screen for modifiers of transgene variegation identifies genes with critical roles in development. Genome Biol (2008) 1.35
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin Investig Drugs (2009) 1.28
Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob Agents Chemother (2008) 1.26
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
Loss-of-function HDAC8 mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, ocular hypertelorism, large fontanelle and X-linked inheritance. Hum Mol Genet (2014) 1.25
The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid Redox Signal (2011) 1.24
Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol (2014) 1.18
Activation and inhibition of histone deacetylase 8 by monovalent cations. J Biol Chem (2009) 1.18
On the inhibition of histone deacetylase 8. Bioorg Med Chem (2010) 1.18
A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. J Am Chem Soc (2010) 1.14
The activity of HDAC8 depends on local and distal sequences of its peptide substrates. Biochemistry (2008) 1.14
Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem (2009) 1.11
Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol Cell Biol (2006) 1.11
Evolution of the arginase fold and functional diversity. Cell Mol Life Sci (2008) 1.09
HDAC8 substrates: Histones and beyond. Biopolymers (2013) 1.08
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene (2012) 1.08
Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors. Plant Cell (2015) 1.06
Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis (2008) 1.04
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J Med Chem (2010) 1.03
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides. J Med Chem (2009) 1.02
Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors. J Med Chem (2009) 1.01
Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res (Phila) (2009) 1.01
Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem (2008) 1.00
Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett (2011) 0.99
Expression, purification, assay, and crystal structure of perdeuterated human arginase I. Arch Biochem Biophys (2007) 0.98
Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg Med Chem Lett (2007) 0.98
Macrocyclic histone deacetylase inhibitors. Curr Top Med Chem (2010) 0.98
Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog (2013) 0.97
The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity. J Biol Chem (2013) 0.97
Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. J Am Chem Soc (2011) 0.97
Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. Nat Immunol (2016) 0.96
Drosophila histone deacetylase-3 controls imaginal disc size through suppression of apoptosis. PLoS Genet (2008) 0.96
Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function . Biochemistry (2010) 0.96
Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders. ACS Chem Biol (2014) 0.95
Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol (2011) 0.95
Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharm Pat Anal (2012) 0.94
Flexibility of Catalytic Zinc Coordination in Thermolysin and HDAC8: A Born-Oppenheimer ab initio QM/MM Molecular Dynamics Study. J Chem Theory Comput (2009) 0.94
Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother (2012) 0.94
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem (2009) 0.93
Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors. J Med Chem (2008) 0.93
Thioredoxin in cancer--role of histone deacetylase inhibitors. Semin Cancer Biol (2006) 0.93
Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis (2009) 0.93
Small molecule inhibitors of zinc-dependent histone deacetylases. Neurotherapeutics (2013) 0.91
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients (2012) 0.91
Histone deacetylase activators: N-acetylthioureas serve as highly potent and isozyme selective activators for human histone deacetylase-8 on a fluorescent substrate. Bioorg Med Chem Lett (2011) 0.91
Structure of prokaryotic polyamine deacetylase reveals evolutionary functional relationships with eukaryotic histone deacetylases. Biochemistry (2011) 0.91
Biological targets and mechanisms of action of natural products from marine cyanobacteria. Nat Prod Rep (2015) 0.90
Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors. Anal Biochem (2010) 0.90
Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy. Chemistry (2015) 0.90
An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme. Biochem J (2007) 0.89
The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. Curr Pharm Des (2010) 0.88
Inhibition and mechanism of HDAC8 revisited. J Am Chem Soc (2014) 0.88
Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets (2012) 0.87
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition. J Med Chem (2013) 0.87
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis (2014) 0.86
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget? ChemMedChem (2015) 0.86
Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.86
Identification of an intrinsic determinant critical for maspin subcellular localization and function. PLoS One (2013) 0.86
Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures. J Am Chem Soc (2009) 0.86
Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8. Biochemistry (2015) 0.86
Maternal cadmium, iron and zinc levels, DNA methylation and birth weight. BMC Pharmacol Toxicol (2015) 0.85
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS One (2015) 0.85
The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg Med Chem Lett (2011) 0.85
Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8. J Am Chem Soc (2013) 0.85
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett (2013) 0.84
Selection of an improved HDAC8 inhibitor through structure-based drug design. Bioinformation (2011) 0.84
The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. Bioorg Med Chem Lett (2012) 0.83
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis (2015) 0.83
Mechanism of N-Acylthiourea-mediated activation of human histone deacetylase 8 (HDAC8) at molecular and cellular levels. J Biol Chem (2015) 0.83
HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine. ACS Chem Biol (2016) 0.82
General Base-General Acid Catalysis in Human Histone Deacetylase 8. Biochemistry (2016) 0.82
Biochemical and Structural Characterization of HDAC8 Mutants Associated with Cornelia de Lange Syndrome Spectrum Disorders. Biochemistry (2015) 0.81
Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations. J Mol Model (2011) 0.80
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. J Med Chem (2014) 0.80
Synthesis and evaluation of N⁸-acetylspermidine analogues as inhibitors of bacterial acetylpolyamine amidohydrolase. Bioorg Med Chem (2013) 0.80
Zinc deficiency enhanced inflammatory response by increasing immune cell activation and inducing IL6 promoter demethylation. Mol Nutr Food Res (2015) 0.79
Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2. Bioorg Med Chem Lett (2012) 0.79
Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia. Front Neurol (2015) 0.79
Quantum chemical study of silanediols as metal binding groups for metalloprotease inhibitors. J Mol Model (2013) 0.79
Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery. Int J Mol Sci (2011) 0.78
Molecular modeling study on tunnel behavior in different histone deacetylase isoforms. PLoS One (2012) 0.78
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Prior image constrained compressed sensing (PICCS): a method to accurately reconstruct dynamic CT images from highly undersampled projection data sets. Med Phys (2008) 7.52
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (2009) 5.00
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
The genome of M. acetivorans reveals extensive metabolic and physiological diversity. Genome Res (2002) 4.58
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem (2004) 3.79
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
Combining the polymerase incomplete primer extension method for cloning and mutagenesis with microscreening to accelerate structural genomics efforts. Proteins (2008) 3.29
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2007) 2.76
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther (2011) 2.48
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem (2006) 2.29
Comparative genomic analysis of archaeal genotypic variants in a single population and in two different oceanic provinces. Appl Environ Microbiol (2002) 2.24
Abdominal CT with model-based iterative reconstruction (MBIR): initial results of a prospective trial comparing ultralow-dose with standard-dose imaging. AJR Am J Roentgenol (2012) 2.13
Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem (2005) 2.07
Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem (2003) 2.06
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A (2007) 2.03
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
Correlations of DDAH1 transcript variants with human endothelial asymmetric dimethylarginine metabolizing activity. Am J Hypertens (2013) 1.98
High temporal resolution and streak-free four-dimensional cone-beam computed tomography. Phys Med Biol (2008) 1.96
Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem (2003) 1.95
Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science (2003) 1.77
Undetermined focal liver lesions on gray-scale ultrasound in patients with fatty liver: characterization with contrast-enhanced ultrasound. J Gastroenterol Hepatol (2008) 1.74
Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine (2006) 1.74
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem (2007) 1.73
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood (2013) 1.69
A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis (2007) 1.68
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem (2011) 1.61
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett (2010) 1.59
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett (2009) 1.56
Crystal structure of TM1367 from Thermotoga maritima at 1.90 A resolution reveals an atypical member of the cyclophilin (peptidylprolyl isomerase) fold. Proteins (2006) 1.51
Finding complex biological relationships in recent PubMed articles using Bio-LDA. PLoS One (2011) 1.45
High-resolution crystal structures and spectroscopy of native and compound I cytochrome c peroxidase. Biochemistry (2003) 1.44
Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One (2008) 1.44
Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure (2002) 1.42
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma (2013) 1.42
The solution structure and interactions of CheW from Thermotoga maritima. Nat Struct Biol (2002) 1.41
Function of human Rh based on structure of RhCG at 2.1 A. Proc Natl Acad Sci U S A (2010) 1.41
Crystal structure of a human aminoacyl-tRNA synthetase cytokine. Proc Natl Acad Sci U S A (2002) 1.40
Surgical treatment and long-term outcomes of thalamic cavernous malformations. World Neurosurg (2012) 1.38
Crystal structures that suggest late development of genetic code components for differentiating aromatic side chains. Proc Natl Acad Sci U S A (2003) 1.36
Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr (2007) 1.36
Alanyl-tRNA synthetase crystal structure and design for acceptor-stem recognition. Mol Cell (2004) 1.34
Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity. Genes Dev (2006) 1.34
Reduced image noise at low-dose multidetector CT of the abdomen with prior image constrained compressed sensing algorithm. Radiology (2011) 1.34
Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int (2002) 1.31
Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci (2010) 1.31
Prior image constrained compressed sensing: implementation and performance evaluation. Med Phys (2012) 1.30
Gene expression response to misfolded protein as a screen for soluble recombinant protein. Protein Eng (2002) 1.30
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A (2007) 1.29
Structure of the γ-D-glutamyl-L-diamino acid endopeptidase YkfC from Bacillus cereus in complex with L-Ala-γ-D-Glu: insights into substrate recognition by NlpC/P60 cysteine peptidases. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 1.28
Temporal resolution improvement using PICCS in MDCT cardiac imaging. Med Phys (2009) 1.28
CD24: from A to Z. Cell Mol Immunol (2010) 1.28
Fragment-based screen against HIV protease. Chem Biol Drug Des (2010) 1.26
Understanding the complexity of temperature dynamics in Xinjiang, China, from multitemporal scale and spatial perspectives. ScientificWorldJournal (2013) 1.26
Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother (2005) 1.25
The TB structural genomics consortium crystallization facility: towards automation from protein to electron density. Acta Crystallogr D Biol Crystallogr (2002) 1.24
Structural basis of murein peptide specificity of a gamma-D-glutamyl-l-diamino acid endopeptidase. Structure (2009) 1.23
Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci (2004) 1.23
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci U S A (2009) 1.22
Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry (2004) 1.22
Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes (2002) 1.22
A general protocol for the crystallization of membrane proteins for X-ray structural investigation. Nat Protoc (2009) 1.21
Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer (2004) 1.21
Two conformations of a crystalline human tRNA synthetase-tRNA complex: implications for protein synthesis. EMBO J (2006) 1.21
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett (2011) 1.20
X-ray crystallographic structures of the Escherichia coli periplasmic protein FhuD bound to hydroxamate-type siderophores and the antibiotic albomycin. J Biol Chem (2002) 1.20
Time-resolved interventional cardiac C-arm cone-beam CT: an application of the PICCS algorithm. IEEE Trans Med Imaging (2011) 1.20
High-resolution structure of the soluble, respiratory-type Rieske protein from Thermus thermophilus: analysis and comparison. Biochemistry (2003) 1.19